ELDN

Eledon Pharmaceuticals, Inc. [ELDN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ELDN Stock Summary

Top 10 Correlated ETFs

ELDN

Top 10 Correlated Stocks

ELDN

In the News

ELDN Financial details

Company Rating
-
Market Cap
40.89M
Income
-39.99M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.64
Forward P/E
-
PEG
0.09
P/S
-
P/B
0.62
P/C
-
P/FCF
-1.15
Quick Ratio
20.56
Current Ratio
21.73
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.88
EPS next Y
-
EPS next Q
-
EPS this Y
-73.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
-33.33%
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-92%
ROE
-101%
ROC
-0.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.07-2.95
52W High
+38.51%
52W Low
+177.01%
RSI
60
Rel Volume
13.66
Avg Volume
75.82K
Volume
1.04M
Perf Week
22.57%
Perf Month
5.73%
Perf Quarter
-27.48%
Perf Half Y
76.44%
-
-
-
-
Beta
0.929
-
-
Volatility
0.29%, 0.22%
Prev Close
-8.88%
Price
2.7701
Change
0%

Something similar

Top by Market Cap
GOOGL
FXAIX
BRYN.DE
MSFT
MIX.JO
Top Correlated ETFs
KJAN
KOCT
KAPR
KJUL
FLPE.L
Top Correlated Stocks
SOFI
WSC
FNWB
MC
AXGN
Similar Market Cap
PBAX
LRDC
ACBAU
XLM.L
MODD

Company Profile

Healthcare Biotechnology
  • Volume Average 75.82K
  • Market Capitalization 40.89M
  • Employee 20
  • CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
  • Headquarters Irvine,CA,US
  • IPO Date 2014-09-17
  • Website https://eledon.com

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.